JPRN-UMIN000041251已完成未知
Retrospective observational study of osimertinib and afatinib for patients with advanced EGFR-mutated non-small cell lung cancer. - Retrospective study of osimertinib and afatinib in EGFR-mutated NSCLC.
Central Japan Lung Study Group (CJLSG)0 个研究点目标入组 557 人开始时间: 2020年7月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 557
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Not recieved afatinib or osimertinib as a monotherapy. 2. Recieved chemotherapy or immunotherapy before monotherapy of afatinib/osimertinib as systemic treatment for advanced non-small cell lung cancer. 3. Cases identified as ineligible by investigator.
研究者
相似试验
招募中
不适用
A prospective observational study of osimertinib as predictive marker against patients with EGFR mutation positive NSCLC.ung CancerJPRN-UMIN000040432Gunma University50
未知
不适用
A prospective observational study of osimertinib as predictive marker against patients with EGFR T790M-positive NSCLC.ung CancerJPRN-UMIN000027233Gunma University45
已完成
不适用
Observational study of osimertinib for patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous EGFR-TKI therapy(WJOG8815LFS)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000034682West Japan Oncology Group33
招募中
4 期
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2)2024-517424-18-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS54
已完成
不适用
A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerPatients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerJPRN-UMIN000027655Division of Thoracic Oncology, Shizuoka cancer center18